Evidence map›Paper›PMID 32285614›Full record

ArticleCancer medicine2020

Association between cancer-specific adverse event triggers and mortality: A validation study.

Saul N Weingart, Jason Nelson, Benjamin Koethe, Omar Yaghi, Stephan Dunning, Albert Feldman, David Kent, Allison Lipitz-Snyderman

Registry-linked trialOpen access · goldAbstract readValidation Study
In one paragraph

Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06151639 (Comparison of The Effects Of General Anesthesia and PECS Block Methods on Blood Leukocyte, Neutrophil, Lymphocyte, and Platelet Counts in Patients With Breast Cancer), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06151639 completednot on this mapstarted 2022, after this paper: background citation

Comparison of The Effects Of General Anesthesia and PECS Block Methods on Blood Leukocyte, Neutrophil, Lymphocyte, and Platelet Counts in Patients With Breast Cancer

TypeobservationalSponsorDr Abdurrahman Yurtaslan Ankara Oncology Training and Research HospitalRan2022 to 2025Enrolled50ConditionsBreast CancerArmsgeneral anesthesia, peripheral nerve blocks
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Saul N WeingartTufts Medical Center, Boston, MA, USA.ORCID 0000-0003-3262-9957
Jason NelsonPredictive Analytics and Comparative Effectiveness Center, Tufts University School of Medicine, Boston, MA, USA.
Benjamin KoethePredictive Analytics and Comparative Effectiveness Center, Tufts University School of Medicine, Boston, MA, USA.
Omar YaghiTufts Medical Center, Boston, MA, USA.
Stephan DunningOptumLabs, Cambridge, MA, USA.
Albert FeldmanOptumLabs, Cambridge, MA, USA.
David KentTufts Medical Center, Boston, MA, USA.
Allison Lipitz-SnydermanMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-2423-2220
Tufts University · USTellabs (Canada) · CAMemorial Sloan Kettering Cancer Center · USTufts Medical Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundAs there are few validated measures of patient safety in clinical oncology, creating an efficient measurement instrument would create significant value. Accordingly, we sought to assess the validity of a novel patient safety measure by examining the association of oncology-specific triggers and mortality using administrative claims data.

methodsWe examined a retrospective cohort of 322 887 adult cancer patients enrolled in commercial or Medicare Advantage products for one year after an initial diagnosis of breast, colorectal, lung, or prostate cancer in 2008-2014. We used diagnosis and procedure codes to calculate the prevalence of 16 cancer-specific "triggers"-events that signify a potential adverse event. We compared one-year mortality rates among patients with and without triggers by cancer type and metastatic status using logistic regression models.

resultsTrigger events affected 19% of patients and were most common among patients with metastatic colorectal (41%) and lung (50%) cancers. There was increased one-year mortality among patients with triggers compared to patients without triggers across all cancer types in unadjusted and multivariate analyses. The increased mortality rate among patients with trigger events was particularly striking for nonmetastatic prostate cancer (1.3% vs 7.5%, adjusted odds ratio 1.96 [95% CI 1.49-2.57]) and nonmetastatic colorectal cancer (4.1% vs 11.7%, 1.44 [1.19-1.75]).

conclusionsThe association between adverse event triggers and poor survival among a cohort of cancer patients supports the validity of a cancer-specific, administrative claims-based trigger tool.

Indexed as

AgedAntineoplastic AgentsDrug-Related Side Effects and Adverse ReactionsFemaleFollow-Up StudiesHumansMaleMiddle AgedMortalityNeoplasmsPatient SafetyPrognosisRetrospective StudiesSurvival RateAntineoplastic Agentsadverse eventsepidemiologyoncologyquality of caretrigger tool

Identifiers

PMID32285614
PMCPMC7300390
OpenAlexW3015415018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.